Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This combination therapy involves the co-infusion of bone marrow-derived hematopoietic stem cells (HSC) and insulin-secreting cells (ISC) trans-differentiated from autologous adipose tissue-derived mesenchymal stem cells (AD-MSC). The approach is designed to treat insulin-dependent diabetes mellitus (IDDM) by leveraging the immunomodulatory properties of HSCs to address autoimmunity while providing a functional source of insulin-producing cells derived from the patient's own fat tissue. The therapy is typically administered under non-myeloablative conditioning to facilitate cell engraftment and has shown potential in clinical case studies for improving glycemic control and reducing exogenous insulin requirements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hematopoietic stem cells + insulin-secreting cells.